Affordable Access

deepdyve-link
Publisher Website

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

Authors
  • Caronna, E.
  • José Gallardo, V.
  • Alpuente, A.
  • Torres-Ferrus, M.
  • Sánchez-Mateo, N.M.
  • Viguera-Romero, J.
  • López-Veloso, A.C.
  • López-Bravo, A.
  • Gago-Veiga, A.B.
  • Irimia Sieira, P.
  • Porta-Etessam, J.
  • Santos-Lasaosa, S.
  • Pozo-Rosich, P.
Type
Published Article
Journal
Neurologia (Barcelona, Spain)
Publisher
Sociedad Española de Neurología. Published by Elsevier España, S.L.U.
Publication Date
Oct 12, 2021
Volume
36
Issue
8
Pages
611–617
Identifiers
DOI: 10.1016/j.nrleng.2021.03.005
PMID: 34654536
PMCID: PMC8506139
Source
PubMed Central
Keywords
Disciplines
  • Original Article
License
Unknown

Abstract

Background and objective CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P  = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.

Report this publication

Statistics

Seen <100 times